Liquid biopsies—tests that look for cancer clues in blood instead of cutting out tissue—have long promised a gentler, faster way to track disease. A team at Massachusetts General Hospital now says it has built a microfluidic device that could make one of the hardest parts of that vision much more practical: finding the vanishingly rare circulating tumor cells, or CTCs, that drift through the bloodstream after breaking away from a solid tumor. In a study reported in Proceedings of the National Academy of Sciences, the group describes the LPCTC-iCHIP, a chip designed to process far larger blood-cell samples than older systems can handle. The advance matters because CTCs are extraordinarily scarce—sometimes just one cell among a billion blood cells—so standard blood draws may contain only a few, or none at all. By working through leukopak samples, which are blood products enriched for white blood cells and other nucleated cells, the device can search a much bigger haystack for those crucial needles. The researchers say the chip boosts the sensitivity of CTC-based testing by roughly 100-fold compared with existing approaches. If that performance holds up in broader use, it could move liquid biopsy closer to becoming a routine tool for diagnosing cancer, choosing treatments, and monitoring how tumors change over time.
Why CTCs Are So Hard to Find
CTCs are valuable because they can offer a real-time snapshot of a patient’s cancer without requiring a surgical or needle biopsy. Doctors and researchers hope to use them to identify mutations, match tumors to drugs, and see whether treatment is working as the disease evolves.
The problem is simple in theory but brutal in practice: there are very few of these cells in blood. In a typical 10-milliliter clinical sample, there may be anywhere from zero to around a dozen CTCs, which makes reliable analysis difficult and sometimes impossible.
A Bigger Sample Changes the Math
The Mass General team tackled that scarcity by moving beyond ordinary blood draws and using leukopak material. A leukopak is a blood-derived sample enriched for nucleated cells, especially white blood cells, and it contains vastly more cells than a standard tube of blood.
That larger sample is both an opportunity and a challenge. It may hold many more CTCs, but it also includes about six billion nucleated cells—far too many for most current sorting systems to process efficiently.
How the LPCTC-iCHIP Works
The new device is a type of microfluidic chip, meaning it manipulates cells as they flow through tiny channels etched into a small device. Instead of trying to directly capture tumor cells based on one cancer marker, the system takes the opposite approach: it removes the normal blood cells and leaves behind what is likely to include the tumor cells.
First, the sample’s white blood cells are labeled with a magnetic tag. The chip then uses on-chip magnetic “microlenses” to pull away most of those tagged white blood cells, clearing out the overwhelming background and enriching the remaining sample for possible CTCs.
Faster and More Flexible Than Earlier Approaches
According to the report, the entire sorting process takes less than an hour. That speed is important because complex cell-processing workflows can damage fragile cells or make the test too cumbersome for clinical use.
The design also gives the system a practical advantage: it is agnostic to cancer type. In plain terms, because the chip removes blood cells rather than hunting for a specific tumor marker, it can work with samples from many different solid tumors, even when cancers do not share the same surface proteins.
Why Throughput Matters So Much
Many alternative CTC isolation technologies can process only about three to five percent of a leukopak. That means most of a valuable sample is effectively left unsearched, and many rare tumor cells are likely missed.
The iCHIP, by contrast, is built for ultrahigh throughput, or the ability to handle a very large volume of cells quickly. The researchers say that allows it to recover thousands more CTCs than competing methods, a difference that could turn a barely detectable signal into something robust enough for genomic testing and repeated monitoring.
What Better Cell Recovery Could Enable
Recovering more intact CTCs is not just a numbers game. Each additional cell can carry DNA, RNA, and protein information that helps reveal how a tumor is behaving, whether it is likely to resist treatment, and how it differs from the original biopsy taken months or years earlier.
That is one reason liquid biopsy has generated so much excitement in oncology. A blood test that can be repeated often, with minimal discomfort, could let doctors watch cancer adapt in near real time rather than relying on occasional invasive tissue sampling.
Why This Matters
If the technology proves reliable outside the lab, it could make cancer monitoring less invasive and more informative at the same time. Patients who cannot easily undergo repeat tissue biopsies might still get molecular testing that helps guide therapy decisions.
Just as important, the chip’s broad, marker-independent design may reduce a common bias in cell capture systems: missing tumor cells that do not display the “right” surface markers. By focusing on removing normal blood cells instead, the approach may widen the range of cancers and cell states that can be studied through blood.
What Comes Next
The promise is significant, but tools like this still need validation in larger clinical studies to show that better cell capture leads to better patient outcomes. Researchers will need to demonstrate not only that the LPCTC-iCHIP finds more tumor cells, but that those extra cells improve diagnosis, treatment selection, and disease monitoring in real-world care.
Even so, the work points toward a future where liquid biopsy is not limited by the rarity of the cells it seeks. If engineers can keep scaling up sensitivity while preserving cell quality, blood-based cancer testing may shift from an exciting possibility to a routine part of precision medicine.